ICU sedation, delirium & recovery
Dexmedetomidine on supraventricular tachycardia in critical illness: a time-dependent propensity score matching study
Main findingResult — go to the resultAbsolute risk difference 5.73%Authors' conclusion
Dexmedetomidine exposure is associated with clinically significant supraventricular tachycardia in critically ill, mechanically ventilated patients.
Study context
- Population
- Critically ill adults intubated within 48 h of admission, 11 hospitals, July 2018–October 2022matched cohort
- Participants
- 7,276 vs 7,276
- Exposure
- Dexmedetomidine exposure vs no dexmedetomidine exposure
- Dexmedetomidinen = 7,276
- Matched controlsn = 7,276reference
- Outcome
- Clinically significant supraventricular tachycardia (heart rate > 100 beats per minute and IV antiarrhythmic drugs)
- Follow-up
- 7 days
Methodological detailstime-dependent propensity score matching, multicentre (11 hospitals)
- Time-dependent propensity score matching
- Multicentre (11 hospitals)
Main finding
As reported in the abstract
Absolute risk difference
5.73%
P < 0.05
Events by group
Observational data: associations, not effects.
Further findings
Supraventricular tachycardia accounting for competing risks
- Dexmedetomidine use remained associated with a higher risk of supraventricular tachycardia
- P < 0.05
Original publication
Dexmedetomidine on supraventricular tachycardia in critical illness: a time-dependent propensity score matching study. Crit Care. Published 17 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →